Market Currents
ImmunoCellular (IMUC) +7% AH after announcing Andrew Gengos, until recently the CEO of private...
-
Monday, December 3, 2012, 4:23 PM ETImmunoCellular (IMUC) +7% AH after announcing Andrew Gengos, until recently the CEO of private Neuraltus Pharmaceuticals, is its new CEO. Chief scientific officer John Yu had been serving as interim CEO since August, when former chief Manish Singh stepped down.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
